Back to Course

2025 PACUPrep BCCCP Preparatory Course

0% Complete
0/0 Steps
  1. Pulmonary

    ARDS
    4 Topics
    |
    1 Quiz
  2. Asthma Exacerbation
    4 Topics
    |
    1 Quiz
  3. COPD Exacerbation
    4 Topics
    |
    1 Quiz
  4. Cystic Fibrosis
    6 Topics
    |
    1 Quiz
  5. Drug-Induced Pulmonary Diseases
    3 Topics
    |
    1 Quiz
  6. Mechanical Ventilation Pharmacotherapy
    5 Topics
    |
    1 Quiz
  7. Pleural Disorders
    5 Topics
    |
    1 Quiz
  8. Pulmonary Hypertension (Acute and Chronic severe pulmonary hypertension)
    5 Topics
    |
    1 Quiz
  9. Cardiology
    Acute Coronary Syndromes
    6 Topics
    |
    1 Quiz
  10. Atrial Fibrillation and Flutter
    6 Topics
    |
    1 Quiz
  11. Cardiogenic Shock
    4 Topics
    |
    1 Quiz
  12. Heart Failure
    7 Topics
    |
    1 Quiz
  13. Hypertensive Crises
    5 Topics
    |
    1 Quiz
  14. Ventricular Arrhythmias and Sudden Cardiac Death Prevention
    5 Topics
    |
    1 Quiz
  15. NEPHROLOGY
    Acute Kidney Injury (AKI)
    5 Topics
    |
    1 Quiz
  16. Contrast‐Induced Nephropathy
    5 Topics
    |
    1 Quiz
  17. Drug‐Induced Kidney Diseases
    5 Topics
    |
    1 Quiz
  18. Rhabdomyolysis
    5 Topics
    |
    1 Quiz
  19. Syndrome of Inappropriate Antidiuretic Hormone (SIADH)
    5 Topics
    |
    1 Quiz
  20. Renal Replacement Therapies (RRT)
    5 Topics
    |
    1 Quiz
  21. Neurology
    Status Epilepticus
    5 Topics
    |
    1 Quiz
  22. Acute Ischemic Stroke
    5 Topics
    |
    1 Quiz
  23. Subarachnoid Hemorrhage
    5 Topics
    |
    1 Quiz
  24. Spontaneous Intracerebral Hemorrhage
    5 Topics
    |
    1 Quiz
  25. Neuromonitoring Techniques
    5 Topics
    |
    1 Quiz
  26. Gastroenterology
    Acute Upper Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  27. Acute Lower Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  28. Acute Pancreatitis
    5 Topics
    |
    1 Quiz
  29. Enterocutaneous and Enteroatmospheric Fistulas
    5 Topics
    |
    1 Quiz
  30. Ileus and Acute Intestinal Pseudo-obstruction
    5 Topics
    |
    1 Quiz
  31. Abdominal Compartment Syndrome
    5 Topics
    |
    1 Quiz
  32. Hepatology
    Acute Liver Failure
    5 Topics
    |
    1 Quiz
  33. Portal Hypertension & Variceal Hemorrhage
    5 Topics
    |
    1 Quiz
  34. Hepatic Encephalopathy
    5 Topics
    |
    1 Quiz
  35. Ascites & Spontaneous Bacterial Peritonitis
    5 Topics
    |
    1 Quiz
  36. Hepatorenal Syndrome
    5 Topics
    |
    1 Quiz
  37. Drug-Induced Liver Injury
    5 Topics
    |
    1 Quiz
  38. Dermatology
    Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
    5 Topics
    |
    1 Quiz
  39. Erythema multiforme
    5 Topics
    |
    1 Quiz
  40. Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS)
    5 Topics
    |
    1 Quiz
  41. Immunology
    Transplant Immunology & Acute Rejection
    5 Topics
    |
    1 Quiz
  42. Solid Organ & Hematopoietic Transplant Pharmacotherapy
    5 Topics
    |
    1 Quiz
  43. Graft-Versus-Host Disease (GVHD)
    5 Topics
    |
    1 Quiz
  44. Hypersensitivity Reactions & Desensitization
    5 Topics
    |
    1 Quiz
  45. Biologic Immunotherapies & Cytokine Release Syndrome
    5 Topics
    |
    1 Quiz
  46. Endocrinology
    Relative Adrenal Insufficiency and Stress-Dose Steroid Therapy
    5 Topics
    |
    1 Quiz
  47. Hyperglycemic Crisis (DKA & HHS)
    5 Topics
    |
    1 Quiz
  48. Glycemic Control in the ICU
    5 Topics
    |
    1 Quiz
  49. Thyroid Emergencies: Thyroid Storm & Myxedema Coma
    5 Topics
    |
    1 Quiz
  50. Hematology
    Acute Venous Thromboembolism
    5 Topics
    |
    1 Quiz
  51. Drug-Induced Thrombocytopenia
    5 Topics
    |
    1 Quiz
  52. Anemia of Critical Illness
    5 Topics
    |
    1 Quiz
  53. Drug-Induced Hematologic Disorders
    5 Topics
    |
    1 Quiz
  54. Sickle Cell Crisis in the ICU
    5 Topics
    |
    1 Quiz
  55. Methemoglobinemia & Dyshemoglobinemias
    5 Topics
    |
    1 Quiz
  56. Toxicology
    Toxidrome Recognition and Initial Management
    5 Topics
    |
    1 Quiz
  57. Management of Acute Overdoses – Non-Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  58. Management of Acute Overdoses – Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  59. Toxic Alcohols and Small-Molecule Poisons
    5 Topics
    |
    1 Quiz
  60. Antidotes and Gastrointestinal Decontamination
    5 Topics
    |
    1 Quiz
  61. Extracorporeal Removal Techniques
    5 Topics
    |
    1 Quiz
  62. Withdrawal Syndromes in the ICU
    5 Topics
    |
    1 Quiz
  63. Infectious Diseases
    Sepsis and Septic Shock
    5 Topics
    |
    1 Quiz
  64. Pneumonia (CAP, HAP, VAP)
    5 Topics
    |
    1 Quiz
  65. Endocarditis
    5 Topics
    |
    1 Quiz
  66. CNS Infections
    5 Topics
    |
    1 Quiz
  67. Complicated Intra-abdominal Infections
    5 Topics
    |
    1 Quiz
  68. Antibiotic Stewardship & PK/PD
    5 Topics
    |
    1 Quiz
  69. Clostridioides difficile Infection
    5 Topics
    |
    1 Quiz
  70. Febrile Neutropenia & Immunocompromised Hosts
    5 Topics
    |
    1 Quiz
  71. Skin & Soft-Tissue Infections / Acute Osteomyelitis
    5 Topics
    |
    1 Quiz
  72. Urinary Tract and Catheter-related Infections
    5 Topics
    |
    1 Quiz
  73. Pandemic & Emerging Viral Infections
    5 Topics
    |
    1 Quiz
  74. Supportive Care (Pain, Agitation, Delirium, Immobility, Sleep)
    Pain Assessment and Analgesic Management
    5 Topics
    |
    1 Quiz
  75. Sedation and Agitation Management
    5 Topics
    |
    1 Quiz
  76. Delirium Prevention and Treatment
    5 Topics
    |
    1 Quiz
  77. Sleep Disturbance Management
    5 Topics
    |
    1 Quiz
  78. Immobility and Early Mobilization
    5 Topics
    |
    1 Quiz
  79. Oncologic Emergencies
    5 Topics
    |
    1 Quiz
  80. End-of-Life Care & Palliative Care
    Goals of Care & Advance Care Planning
    5 Topics
    |
    1 Quiz
  81. Pain Management & Opioid Therapy
    5 Topics
    |
    1 Quiz
  82. Dyspnea & Respiratory Symptom Management
    5 Topics
    |
    1 Quiz
  83. Sedation & Palliative Sedation
    5 Topics
    |
    1 Quiz
  84. Delirium Agitation & Anxiety
    5 Topics
    |
    1 Quiz
  85. Nausea, Vomiting & Gastrointestinal Symptoms
    5 Topics
    |
    1 Quiz
  86. Management of Secretions (Death Rattle)
    5 Topics
    |
    1 Quiz
  87. Fluids, Electrolytes, and Nutrition Management
    Intravenous Fluid Therapy and Resuscitation
    5 Topics
    |
    1 Quiz
  88. Acid–Base Disorders
    5 Topics
    |
    1 Quiz
  89. Sodium Homeostasis and Dysnatremias
    5 Topics
    |
    1 Quiz
  90. Potassium Disorders
    5 Topics
    |
    1 Quiz
  91. Calcium and Magnesium Abnormalities
    5 Topics
    |
    1 Quiz
  92. Phosphate and Trace Electrolyte Management
    5 Topics
    |
    1 Quiz
  93. Enteral Nutrition Support
    5 Topics
    |
    1 Quiz
  94. Parenteral Nutrition Support
    5 Topics
    |
    1 Quiz
  95. Refeeding Syndrome and Specialized Nutrition
    5 Topics
    |
    1 Quiz
  96. Trauma and Burns
    Initial Resuscitation and Fluid Management in Trauma
    5 Topics
    |
    1 Quiz
  97. Hemorrhagic Shock, Massive Transfusion, and Trauma‐Induced Coagulopathy
    5 Topics
    |
    1 Quiz
  98. Burns Pharmacotherapy
    5 Topics
    |
    1 Quiz
  99. Burn Wound Care
    5 Topics
    |
    1 Quiz
  100. Open Fracture Antibiotics
    5 Topics
    |
    1 Quiz

Participants 432

  • Allison Clemens
  • April
  • ababaabhay
  • achoi2392
  • adhoward1
Show more
Lesson 54, Topic 3
In Progress

Pharmacotherapy Strategies in ICU Management of Sickle Cell Crisis

Lesson Progress
0% Complete
Pharmacotherapy in ICU Management of Sickle Cell Crisis

Pharmacotherapy Strategies in ICU Management of Sickle Cell Crisis

Objectives Icon A checkmark inside a circle, symbolizing achieved goals.

Learning Objective

Implement evidence-based, multimodal pharmacotherapy for vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) in critically ill patients, including fluid management, potent analgesia, and transfusion strategies tailored to organ dysfunction.

1. Intravenous Hydration

Summary: Rapid restoration of intravascular volume reduces blood viscosity, improves microvascular flow, and inhibits sickling. The primary goal is to achieve euvolemia while meticulously avoiding fluid overload, which can precipitate or worsen acute chest syndrome (ACS).

Agent Selection & Dosing

Isotonic crystalloids are the mainstay of initial resuscitation. The choice between normal saline and balanced salt solutions like Lactated Ringer’s is often guided by the patient’s acid-base status and comorbidities.

  • Initial Bolus: A common starting point is 20 mL/kg of isotonic crystalloid administered intravenously over 1 hour.
  • Maintenance Rate: Following the bolus, a maintenance rate of 1.5 to 2 times the standard calculated rate (e.g., 4-2-1 rule) is often used until euvolemia is achieved and urine output is adequate.

Monitoring & Pitfalls

Close monitoring is critical to guide therapy and prevent complications. This includes:

  • Outputs: Hourly urine output, targeting >0.5 mL/kg/hr.
  • Volume Status: Daily weights, strict fluid balance, and dynamic assessments like point-of-care ultrasound (POCUS) of the inferior vena cava.
  • Lung Water: Clinical assessment for rales and monitoring for worsening oxygenation, which may signal incipient ACS.
Warning IconAn exclamation mark inside a triangle, indicating a warning. Pitfalls & Contraindications

Risk of Fluid Overload: Excessive volume administration is a primary iatrogenic risk, potentially precipitating or worsening ACS. In patients with underlying heart failure or renal impairment, fluid rates must be conservative, and early consideration of diuretics may be necessary if signs of overload appear despite ongoing VOC.

Pearl IconA shield with an exclamation mark, indicating a clinical pearl. Clinical Pearl

Use point-of-care ultrasound (POCUS) to assess IVC diameter and collapsibility to guide fluid titration in real time. While no definitive trial favors Normal Saline versus Lactated Ringer’s, LR may be preferred to avoid the hyperchloremic metabolic acidosis associated with large volumes of NS.

2. Opioid-Based Analgesia

Summary: Mu-receptor agonists remain the cornerstone for managing severe VOC pain. The strategy involves rapid initial control with loading doses followed by patient-controlled analgesia (PCA) or continuous infusions, with the choice of agent tailored to renal function and hemodynamic stability.

Comparison of Intravenous Opioids for Vaso-Occlusive Crisis
Agent Key Features Clinical Considerations
Morphine Cost-effective, well-studied. Active metabolites (M6G, M3G) accumulate in acute kidney injury (AKI), increasing risk of neurotoxicity and respiratory depression. Can cause histamine release.
Hydromorphone Potent, fewer active metabolites than morphine. Generally a safer choice in mild-to-moderate renal impairment. Less histamine release.
Fentanyl Rapid onset, short duration, no active metabolites. Preferred agent in severe renal failure, continuous renal replacement therapy (CRRT), and hemodynamic instability. Ideal for continuous infusion.

Dosing Protocols

  • Loading Dose (Opioid-Naïve): Morphine 0.1 mg/kg IV or Hydromorphone 0.015 mg/kg IV.
  • Patient-Controlled Analgesia (PCA): A common approach that improves patient satisfaction. An example morphine PCA is a basal rate of 0.02 mg/kg/hr, a demand dose of 0.02 mg/kg, and a 10-minute lockout.
  • Fentanyl Infusion: For severe, refractory pain or in mechanically ventilated patients, an infusion of 1–2 µg/kg/hr can be initiated, with boluses of 25–50 µg for breakthrough pain.
Controversy IconA chat bubble with a question mark, indicating a point of controversy or debate. Controversy: Basal Infusions vs. Intermittent Boluses

The use of a continuous basal infusion with PCA is debated. While it may provide more consistent analgesia, it can also accelerate the development of tolerance and potentially increase the risk of respiratory depression. An alternative strategy is to use only patient-activated demand doses, which may reduce the total opioid dose administered.

3. Adjunctive Analgesics and Anti-inflammatories

Summary: A multimodal approach using non-opioid adjuncts can enhance analgesia, reduce total opioid consumption, and target the underlying inflammatory cascade of VOC. However, each agent carries specific risks that must be weighed against its benefits.

Adjunctive Therapies in Sickle Cell Crisis
Agent Class Mechanism & Use Dosing Example Key Contraindications
NSAIDs COX inhibition reduces prostaglandin-mediated inflammation. Used for mild-to-moderate pain. Ketorolac 15–30 mg IV q6h (max 5 days) Acute kidney injury (AKI), active peptic ulcer disease, thrombocytopenia.
Corticosteroids Suppresses inflammatory cytokines and adhesion molecules. Used for ACS, not isolated VOC. Dexamethasone 0.3 mg/kg IV daily Uncontrolled hyperglycemia, systemic fungal infection. Use with caution.
Ketamine NMDA antagonism mitigates central sensitization and opioid tolerance. For opioid-refractory pain. Infusion: 0.1–0.3 mg/kg/hr IV Active psychosis, severe coronary artery disease (relative). Monitor for emergence reactions.
Controversy IconA chat bubble with a question mark, indicating a point of controversy or debate. Corticosteroid Use

While corticosteroids can reduce the length of stay and inflammatory burden in ACS, their use is controversial due to a well-documented risk of triggering a rebound VOC within 48-72 hours of discontinuation. Their use should be reserved for moderate-to-severe ACS and avoided for uncomplicated VOC pain.

Pearl IconA shield with an exclamation mark, indicating a clinical pearl. Opioid-Sparing with Ketamine

In patients with high opioid tolerance or refractory pain, a sub-anesthetic infusion of ketamine (0.1–0.3 mg/kg/hr) can significantly reduce total opioid consumption (often by ~30%) and blunt the development of opioid-induced hyperalgesia.

4. Empiric Antibiotic Therapy

Summary: Given the high mortality of ACS and the difficulty in distinguishing it from pneumonia, prompt initiation of broad-spectrum antibiotics is crucial for any patient with fever and a new pulmonary infiltrate. Therapy should be re-evaluated and de-escalated at 48-72 hours based on clinical response and culture data.

Empiric Regimen

The standard empiric regimen targets common community-acquired and atypical pathogens:

  • Third-Generation Cephalosporin: Ceftriaxone 2 g IV every 24 hours.
  • Macrolide: Azithromycin 500 mg IV or PO every 24 hours.

Dosing in Organ Dysfunction

Adjustments are often necessary in the critically ill:

  • Renal Dysfunction: Azithromycin may require dose adjustment. Hydrophilic agents like beta-lactams require more frequent dosing or extended infusions during CRRT to account for clearance by the circuit.
  • Hepatic Dysfunction: Ceftriaxone is primarily cleared by the liver; dose modification is typically only needed in severe hepatic failure.

5. Transfusion Strategies

Summary: Red blood cell (RBC) transfusion is a key therapy to alleviate anemia, improve oxygen-carrying capacity, and dilute the concentration of sickle hemoglobin (HbS). The choice between simple versus exchange transfusion depends on the clinical indication and severity of illness.

A. Simple Transfusion

  • Indications: Acute symptomatic anemia (typically Hb < 6–7 g/dL) or hemodynamic instability related to anemia.
  • Protocol: Administer 10–15 mL/kg of packed RBCs over 2–4 hours. The goal is to raise the hemoglobin but avoid hyperviscosity; a post-transfusion target of Hb ≤10 g/dL is recommended.
  • Monitoring: Pre- and post-transfusion hemoglobin, vital signs, and signs of volume overload. Use extended antigen-matched blood to minimize alloimmunization risk.

B. Exchange Transfusion

  • Indications: Severe ACS with hypoxemia, acute stroke, multi-organ failure, or hyperhemolysis syndrome.
  • Goal: To rapidly reduce the HbS fraction to less than 30% while maintaining a stable total hemoglobin level.
  • Technique: Automated erythrocytapheresis is the preferred method as it is more efficient and isovolemic. Manual exchange is an alternative if apheresis is unavailable.
  • Complications: Monitor closely for hypocalcemia (due to citrate anticoagulant), iron overload (with chronic transfusions), and vascular access issues.

6. PK/PD and Organ Dysfunction Considerations

Summary: Critical illness profoundly alters drug pharmacokinetics (PK) and pharmacodynamics (PD). Proactive dosing adjustments for opioids, antibiotics, and adjuncts are essential, particularly in the setting of renal or hepatic failure.

  • Renal Replacement Therapy (CRRT):
    • Avoid opioids with active metabolites that are renally cleared (morphine, codeine). Fentanyl and hydromorphone are preferred.
    • Increase the dosing frequency or use extended infusions for hydrophilic antibiotics (e.g., beta-lactams, vancomycin) to overcome clearance by the CRRT circuit.
  • Hepatic Dysfunction:
    • Use NSAIDs and corticosteroids with caution due to risks of coagulopathy and altered metabolism.
    • Monitor for drug accumulation and exaggerated effects.
  • Drug-Drug Interactions:
    • Be vigilant for QT prolongation when combining agents like azithromycin and methadone.
    • Monitor for serotonin syndrome when opioids are used concurrently with serotonergic agents like SSRIs.
Pearl IconA shield with an exclamation mark, indicating a clinical pearl. Kinetic GFR Estimation

In patients with acute kidney injury, static GFR estimates based on a single serum creatinine value are inaccurate. Use kinetic GFR calculators, which account for the rate of change in creatinine, to provide a more accurate assessment of renal function for drug dosing, especially for nephrotoxic or renally-cleared medications.

7. Clinical Decision Algorithms

Summary: A structured, protocol-driven approach to therapy improves outcomes. Clear triggers for escalating and de-escalating care ensure timely interventions and facilitate a smooth transition out of the ICU.

Sickle Cell Crisis ICU Management Algorithm A flowchart showing the escalation and de-escalation pathway for managing sickle cell crisis in the ICU. It starts with initial therapy, moves to escalation triggers, lists advanced options, then shows de-escalation triggers and transition of care steps. Initial Therapy (First 24h) IV Fluids + PCA/Opioids + Scheduled NSAIDs (if no CI) Escalation Triggers • Pain ≥7/10 despite optimal therapy • New/worsening hypoxemia (ACS) • Rising inflammatory markers Advanced Options 1. Add Ketamine Infusion 2. Corticosteroids (for ACS) 3. Exchange Transfusion Re-assess De-escalation Triggers • Pain ≤3/10 for >12 hours • O2 stable on ≤2L NC • Hemodynamically stable Transition of Care Switch to PO meds, taper PCA
Figure 1: ICU Management Algorithm for Sickle Cell Crisis. This algorithm outlines a structured approach, starting with initial therapies and defining clear triggers for escalation to advanced options or de-escalation toward transition of care.

References

  1. Uwaezuoke SN, Ayuk AC, Ndu IK, et al. Vaso-occlusive crisis in sickle cell disease: current paradigm on pain management. J Pain Res. 2018;11:3141–3150.
  2. Brandow AM, Carroll CP, Creary S, et al. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv. 2020;4(12):2656–2701.
  3. Tanabe P, Silva S, Bosworth HB, et al. A randomized trial comparing two vaso-occlusive episode protocols in sickle cell disease. Am J Hematol. 2018;93(2):159–168.
  4. A Compendium of Transfusion Practice Guidelines. Edition 4.0. January 2021.
  5. Guideline Compendium on ICU management of sickle cell crisis [Internal Document]. 2021.
  6. Value of Kinetic Glomerular Filtration Rate Estimation on Medication Dosing in Acute Kidney Injury. 2021.